Patent: 10,087,237
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 10,087,237
Title: | Isoform enriched antibody preparation and method for obtaining it |
Abstract: | Herein is reported a method for producing an antibody preparation comprising the steps of a) applying a buffered solution comprising different isoforms of an antibody to a cation exchange chromatography material, b) applying a first solution with a first conductivity to the cation exchange chromatography material, whereby the antibody isoforms remain bound to the cation exchange chromatography material, and c) applying a second solution with a second conductivity to the cation exchange chromatography material and thereby obtaining the antibody preparation, whereby the conductivity of the second solution exceeds the conductivity of the first solution by not more than 10%. |
Inventor(s): | Falkenstein; Roberto (Munich, DE), Schwendner; Klaus (Weilheim, DE), Spensberger; Bernhard (Eberfing, DE) |
Assignee: | F. HOFFMANN-LA ROCHE AG (Nutley, NJ) |
Application Number: | 14/934,866 |
Patent Claims: | see list of patent claims |
Details for Patent 10,087,237
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | See Plans and Pricing | 2030-12-21 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | See Plans and Pricing | 2030-12-21 |
Genentech, Inc. | PERJETA | pertuzumab | Injection | 125409 | 06/08/2012 | See Plans and Pricing | 2030-12-21 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | See Plans and Pricing | 2030-12-21 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |